Interfant-21 Study on Blinatumomab for Infants with KMT2A-rearranged ALL
The Interfant-21 study evaluates blinatumomab in infants under 1 year with KMT2A-rearranged acute lymphoblastic leukemia.
Phase III
Oncology / Acute Lymphoblastic Leukemia
Status
Active
Sponsor
Amgen
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The Interfant-21 study is critical as it evaluates blinatumomab for a vulnerable pediatric population, potentially establishing it as a key treatment in pediatric oncology. Success could significantly enhance Amgen's portfolio and improve outcomes for high-risk infants with leukemia.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor trial results and any subsequent regulatory filings or partnerships related to pediatric leukemia treatments.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.